BioSpace News Archive

Global heart health leader OMRON Healthcare announced an evolution of its Going for Zero mission to eliminate heart attack and stroke with increased focus on atrial fibrillation, expanded education initiatives, and advancement of its digital health transformation to support a healthcare system facing staffing shortages and crisis-level health inequities.

TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced it will report results for the fourth quarter ended December 31, 2023, after the close of the financial markets on Monday, April 1, 2024, and will hold a conference call at 4:30 p.m. ET that day.

Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that President and CEO, Harry Simeonidis, and CFO, Spiro Sakiris, are scheduled to present at the LD Micro Invitational XIV Investor Conference to be held on April 8-9, 2024 in New York City.

Enveric Biosciences, a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, provided a corporate update and reported financial results for the fourth quarter of 2023 and fiscal year ended December 31, 2023.

Bristol Myers Squibb unveiled a $1.8 million initiative to advance health equity by addressing social determinants of health in four countries with underserved patient needs, including Brazil, India, Thailand, and the United Kingdom.

United Therapeutics Corporation, a public benefit corporation, announced the online availability of a review manuscript titled “Physiological Basis for Xenotransplantation from Genetically-Modified Pigs to Humans: A Review,” in the journal Physiological Reviews.

Theralase® Technologies Inc. announced that it is hosting Advisory Board meetings to present the latest Study II interim clinical data to its Principal Investigators at the Canadian Urological Association Bladder Cancer Forum and the American Urology Association, respectively.

Moderna, Inc. announced that mRNA-1283, the Company’s next-generation COVID-19 vaccine, has successfully met the primary endpoints of its Phase 3 clinical trial, demonstrating a higher immune response against SARS-CoV-2 when compared to mRNA-1273.222, Moderna’s licensed COVID-19 vaccine.

AmeboGenesis™ has achieved a significant milestone with the introduction of a sustainable Amebocyte production process.

Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”) announced multiple scientific presentations at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting being held April 5-8 in Boston, Massachusetts.